Health

CSTONE ANNOUNCED NEW DRUG APPROVAL OF CEJEMLY® (SUGEMALIMAB) IN CHINA TO POTENTIALLY RESHAPE THE LANDSCAPE OF IMMUNO-ONCOLOGY THERAPY IN LUNG CANCER

CStone Pharmaceuticals (the “Company” or “CStone“) is pleased to announce that the National Medical Products Administration (“NMPA“) of China has approved the new drug application (“NDA“) of anti-PD-L1 monoclonal antibody Cejemly® (sugemalimab) in combination with chemotherapy for treatment-naïve metastatic (stage IV) non-small cell lung cancer (“non-small cell lung caner” or…

thaipr.net

21 ธ.ค. 64

World Health Organization Grants Second Emergency Use Listing for Novavax COVID-19 Vaccine

– Nuvaxovid™ COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]) listed for emergency use by the WHO – EUL for Nuvaxovid complements listing for Novavax vaccine manufactured and marketed by Serum Institute of India as Covovax™ – EUL by WHO is a prerequisite for exports to numerous countries participating in the COVAX Facility Novavax, Inc. (Nasdaq: NVAX), a biotechnology company […]

thaipr.net

21 ธ.ค. 64

European Commission Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine

Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) is the first protein-based COVID-19 vaccine authorized for use in Europe Novavax and the European Commission previously announced an advance purchase agreement for up to 200 million doses through 2023 Authorization follows positive recommendation by European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) Novavax, Inc. (Nasdaq: NVAX), […]

thaipr.net

21 ธ.ค. 64

Novavax Receives Positive European Medicines Agency Recommendation for Conditional Marketing Authorization of its COVID-19 Vaccine

European Commission decision on conditional marketing authorization expected imminently Upon authorization, Nuvaxovid™ (also known as NVX-CoV2373) will be the first protein-based COVID-19 vaccine available in Europe Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Medicines Agency (EMA) has…

thaipr.net

21 ธ.ค. 64

Novavax and Serum Institute of India Announce World Health Organization Grants Emergency Use Listing for NVX-CoV2373 COVID-19 Vaccine

First EUL granted by WHO for a protein-based COVID-19 vaccine EUL vaccine manufactured and marketed by SII as COVOVAX™ WHO EUL for Nuvaxovid™ currently under assessment; will be completed following European Medicines Agency (EMA) review Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute […]

thaipr.net

20 ธ.ค. 64

Debiopharm Further Explores the Potential of its Potent, Highly Selective WEE1 Inhibitor Debio 0123 In Phase 1 Cancer Study

Dose escalation, monotherapy trial launched to access the safety and preliminary anti-tumor activity of Debio 0123 in the treatment of advanced solid tumors Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today the first patient treated in the newly launched open-label, phase I study evaluating Debio 0123, an oral, potent and highly selective WEE1 inhibitor, as monotherapy […]

thaipr.net

16 ธ.ค. 64

Argon Medical Devices, Inc. Acquires Matrex Mold and Tool, Inc.

Argon Medical Devices, Inc., a leading manufacturer of medical devices for interventional procedures, announced the acquisition of Wisconsin-based Matrex Mold and Tool, Inc., a custom mold manufacturer for plastic injection molding. Matrex produces metal injection production and prototype molds for the medical device, residential, and automotive industries, and has done so since 1985. Argon was a […]

thaipr.net

15 ธ.ค. 64
1 … 85 86 87 88 89 … 128

Copyright © 2025 Dataxet Limited (บริษัท ดาต้าเซ็ต จำกัด). All Rights Reserved.